Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + capecitabine + trastuzumab + MM-111
- Development stage
- Phase 1
- Lead developer
- Merrimack Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of three established anticancer agents—cisplatin, capecitabine, and trastuzumab—plus the investigational agent MM‑111. Cisplatin is a platinum-based chemotherapy that forms DNA crosslinks and induces apoptosis in rapidly dividing cells. Capecitabine is an oral prodrug of 5-fluorouracil, inhibiting thymidylate synthase and interfering with DNA synthesis. Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ERBB2), blocking downstream signaling and mediating antibody-dependent cellular cytotoxicity in HER2-positive cancers[1][4][8]. MM‑111 is a bispecific recombinant fusion protein designed to inhibit both HER2 and HER3 receptors by binding to their extracellular domains, thereby disrupting neuregulin-mediated signaling pathways critical for tumor cell survival in certain cancers[6]. This combination has been investigated primarily for advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
- Brand names
- Platinol (cisplatin)Xeloda (capecitabine)Herceptin (trastuzumab)
- Other names
- CDDP (cisplatin)XELODA (capecitabine)rhuMAb HER2 (trastuzumab)
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)TS (Thymidylate synthase)NRG1 (Neuregulin-1)
Beyond the preview
Go deeper on cisplatin + capecitabine + trastuzumab + MM-111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + capecitabine + trastuzumab + MM-111.